The goal of this UMI proposal is to address the technological, analytical, and ethical challenges that prevent the optimal use of DNA sequencing to improve treatment of diseases and life planning for patients and their families. High-throughput DNA sequencing will be applied to meet the major diagnostic needs of children with developmental delay, intellectual disability, and related health problems (""""""""DD/ID""""""""). DD/ID disorders inflict life-long suffering for affected children and their families, and are a major heath care and economic burden to society. They are generally highly likely driven by one or a few highly penetrant, often de novo, mutations in any given family, but most children cannot be accurately diagnosed, making treatment and family counseling difficult. Indeed, many affected families undergo a """"""""diagnostic odyssey"""""""", involving years of testing and doctor visits without a specific diagnosis. This proposal builds collaboration between genomics researchers at the Hudson Alpha Institute, local medical geneticists affiliated with the University of Alabama at Birmingham, and investigators at the University of Louisville interested in the ethical, legal, and social consequences of genetic information in the clinic. 600 children with DD/ID and their parents will be enrolled, consented, and questioned about their medical experiences and expectations about genetic information. 500 of these children and their parents will be subjected to a 2-stage sequencing plan: 1) """"""""whole exome sequencing"""""""" and 2) """"""""CNV sequencing"""""""". The former is a cost-effective strategy for identifying relevant variants, particularl for the early onset, severe, and often de novo phenotypes of DD/ID. The latter is a novel strategy with great potential to identify relevant regulatory mutations, which are ignored in typical clinical sequencing strategies. Medically relevant variants, either causal for DD/ID or incidental but predictive for other diseases, will be returned to the family by a medical geneticis and genetics counselor. Follow-up questionnaires and interviews will be used to determine the impact of the returned genomic information on clinical care, family planning, and other aspects of self-perception and well-being that may be altered as a result of the genetic diagnosis and incidental findings. Related questions about risks and benefits of probabilistic information and genomic information that does not lead to specific treatments will also be studied. This highly innovative study design will address a significant clinical need and important unmet challenges that slow or dilute the effectiveness of genomic information in the clinic.
New DNA sequencing technologies hold great promise to impact patients and their families, especially those with severe diseases driven by genetic variants. However, unmet challenges slow progress in genomic medicine. This proposal defines an innovative study to improve diagnoses for children with developmental delay, intellectual disability, and related problems, and also to evaluate how the affected children and their families respond to and benefit from genome-based changes to their diagnosis and clinical care.
|Biesecker, B B; Woolford, S W; Klein, W M P et al. (2017) PUGS: A novel scale to assess perceptions of uncertainties in genome sequencing. Clin Genet 92:172-179|
|Bowling, Kevin M; Thompson, Michelle L; Amaral, Michelle D et al. (2017) Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med 9:43|
|Manolio, Teri A; Fowler, Douglas M; Starita, Lea M et al. (2017) Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. Cell 169:6-12|
|Harms, Frederike Leonie; Girisha, Katta M; Hardigan, Andrew A et al. (2017) Mutations in EBF3 Disturb Transcriptional Profiles and Cause Intellectual Disability, Ataxia, and Facial Dysmorphism. Am J Hum Genet 100:117-127|
|O'Daniel, Julianne M; McLaughlin, Heather M; Amendola, Laura M et al. (2017) A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genet Med 19:575-582|
|Brothers, Kyle B; East, Kelly M; Kelley, Whitley V et al. (2017) Eliciting preferences on secondary findings: the Preferences Instrument for Genomic Secondary Results. Genet Med 19:337-344|
|Blanchet, Patricia; Bebin, Martina; Bruet, Shaam et al. (2017) MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus. PLoS Genet 13:e1006957|
|Møller, Rikke S; Weckhuysen, Sarah; Chipaux, Mathilde et al. (2016) Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy. Neurol Genet 2:e118|
|Amendola, Laura M; Jarvik, Gail P; Leo, Michael C et al. (2016) Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet 98:1067-1076|
|Amendola, Laura M; Jarvik, Gail P; Leo, Michael C et al. (2016) Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet 99:247|
Showing the most recent 10 out of 22 publications